Effect of Low-Calorie Diet and Lifestyle Intervention on Reversal of T2DM

NCT ID: NCT05925946

Last Updated: 2023-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-01

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An increase in body fat, even when within the normal BMI range is one of the essential drivers of T2DM in Asian Indians. In this context, the relationship between excess hepatic fat and pancreatic fat appears to be necessary. A low-calorie (high protein and low carb) vegetarian diet with appropriate exercise, in a protocol similar to the DiRECT study, may lead to weight loss, reversal of diabetes, and decrease in ectopic fat.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetes is one of the biggest global public health problems. India has 100 million people living with diabetes as per the 2023 data. Reversal of T2DM, the holy grail of diabetes management, was not deemed possible until recently. Primary care-led weight management for remission of type 2 diabetes (DiRECT) trial has been conducted in obese patients with T2DM patients for a period of 2 years in the UK. Research on the effect of dietary intervention would be necessary for Asian Indians since liver fat deposition is more severe than in white Caucasians. Although some nutritionists and physicians are replicating methods of DiRECT study in their patients, it is not clear if similar diets will work effectively in community-dwelling Asian Indians.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus PreDiabetes Diet Habit

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Type 2 Diabetes, Low calorie diet, Asian Indians, hepatic fat, pancreatic fat

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group

1. Phase1 (Partial diet replacement) (850 Kcal/day) (12-20 weeks)):
2. Phase 2 (Gradual increase in calories) (20-28 weeks) (1100 Kcal/day):
3. Phase 3 (Weight loss maintenance) (29-104 weeks) (up to 1200Kcal/day) :

Group Type EXPERIMENTAL

CURE-DM

Intervention Type DIETARY_SUPPLEMENT

1. This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.
2. These subjects will be randomized into two groups by computer-generated randomization list using variable block size.
3. Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice.

Control Group

Subjects will be given routine care for diabetes and obesity management with no change in medication. The meal plan for the control group will consist of 1400 Kcal/day achieved through small frequently distributed meals constituting around 15% of protein, 60% of carbohydrates and 25% of fat; with a menu resembling standard Indian dietary patterns and meal combinations.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CURE-DM

1. This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.
2. These subjects will be randomized into two groups by computer-generated randomization list using variable block size.
3. Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with T2DM within the previous 3 years
* Age 20-65 years
* BMI \>25-45kg/m2
* HbA1c\> 6.5% at baseline (on current treatment, if any)

Exclusion Criteria

* Recent or screening HbA1c of 9% or higher
* Weight loss of \>5 kg within the previous 6 months
* Significant cardiopulmonary
* Hepatic, or another endocrine disease
* Current participation in any other research drug study in the previous three months
* Past history of bariatric surgery Malignancy other than minor skin lesions and Possibility of pregnancy
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Science and Technology, India

OTHER_GOV

Sponsor Role collaborator

Diabetes Foundation, India

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anoop Misra, MD

Role: CONTACT

Phone: 01141759672

Email: [email protected]

Surya Prakash, PhD+Post Doc

Role: CONTACT

Phone: 01141759672

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-1312

Identifier Type: -

Identifier Source: org_study_id